2 recruiting, 1 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 2 | Recruiting 2 |
Follow High-grade B-cell Lymphoma (HGBL): new trials by email Literature Review of High-grade B-cell Lymphoma (HGBL) trials Research Report on High-grade B-cell Lymphoma (HGBL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Loncastuximab Tesirine and Epcoritamab - Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL) | Phase 2 | Recruiting | Universität Münster | 120 | 2025-10-31 | 2026-07-30 |
| Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients TC011 - Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | TICAROS Co., Ltd. | 98 | 2023-08-03 | 2026-03-16 |
| Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma fimepinostat, Rituximab, venetoclax - Lymphoma, Relapsed Lymphoma | Phase 1 | Completed | Curis, Inc. | 106 | 2012-12-01 | 2021-05-06 |
Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma (1) · Lymphoma, Follicular (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Lymphoma (2)
CUDC-907 (1) · Rituximab (1) · fimepinostat (1) · loncastuximab tesirine (1) · venetoclax (1)
Curis, Inc. (1) · TICAROS Co., Ltd. (1) · Universität Münster (1)
Germany (1) · South Korea (1) · United States (1)
2023 (1)